Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outset Medical (OM) Finished Goods (2019 - 2025)

Historic Finished Goods for Outset Medical (OM) over the last 7 years, with Q4 2025 value amounting to $13.1 million.

  • Outset Medical's Finished Goods fell 4470.92% to $13.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $13.1 million, marking a year-over-year decrease of 4470.92%. This contributed to the annual value of $13.1 million for FY2025, which is 4470.92% down from last year.
  • Outset Medical's Finished Goods amounted to $13.1 million in Q4 2025, which was down 4470.92% from $15.8 million recorded in Q3 2025.
  • Over the past 5 years, Outset Medical's Finished Goods peaked at $26.4 million during Q2 2024, and registered a low of $6.1 million during Q1 2021.
  • Its 5-year average for Finished Goods is $17.8 million, with a median of $17.6 million in 2022.
  • In the last 5 years, Outset Medical's Finished Goods surged by 30000.0% in 2021 and then tumbled by 4617.41% in 2023.
  • Outset Medical's Finished Goods (Quarter) stood at $15.0 million in 2021, then surged by 44.95% to $21.8 million in 2022, then rose by 0.06% to $21.8 million in 2023, then grew by 8.86% to $23.7 million in 2024, then crashed by 44.71% to $13.1 million in 2025.
  • Its Finished Goods stands at $13.1 million for Q4 2025, versus $15.8 million for Q3 2025 and $17.8 million for Q2 2025.